Get the Stockscreener App
13.50
3.07%
-0.04
Avalo Therapeutics Inc stock is traded at $13.50, with a volume of 2,356.
It is down -3.07% in the last 24 hours and up +34.36% over the past month.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$13.54
Open:
$13.23
24h Volume:
2,356
Relative Volume:
0.09
Market Cap:
$131.34M
Revenue:
$1.93M
Net Income/Loss:
$-31.54M
P/E Ratio:
-6.3084
EPS:
-2.14
Net Cash Flow:
$-30.68M
1W Performance:
-3.50%
1M Performance:
+34.36%
6M Performance:
-8.61%
1Y Performance:
+12,605%
1-Day Range:
$12.85
$13.23
1-Week Range:
$11.98
$13.60
52-Week Range:
$0.0333
$34.46
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
540 GAITHER ROAD, ROCKVILLE
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
Avalo Therapeutics Inc Stock (AVTX) Latest News
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at HC Wainwright - Defense World
When (AVTX) Moves Investors should Listen - Stock Traders Daily
Avalo Therapeutics begins Phase 2 trial for hidradenitis suppurativa - Investing.com
Avalo Therapeutics maintains Outperform rating from Oppenheimer - Investing.com
Avalo Therapeutics begins Phase 2 trial for hidradenitis suppurativa By Investing.com - Investing.com UK
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial - GlobeNewswire
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - Yahoo Finance
Ikarian Capital, LLC Adjusts Stake in Avalo Therapeutics Inc - GuruFocus.com
(AVTX) Technical Pivots with Risk Controls - Stock Traders Daily
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Expands By 38.1% - Defense World
Avalo Therapeutics: Pioneering Biotech Solutions for Immune Disorders - The China Perspective
Affinity Asset Advisors LLC Acquires 35,000 Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
Where are the Opportunities in (AVTX) - Stock Traders Daily
Logos Global Management LP Purchases New Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
How To Trade (AVTX) - Stock Traders Daily
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 7.8% - Defense World
Avalo Therapeutics regains Nasdaq compliance - Investing.com
Avalo Announces Participation in September Investor Conferences - GlobeNewswire
Financial Health Report: Avalo Therapeutics Inc (AVTX)’s Ratios Tell a Tale - The Dwinnex
Trading (AVTX) With Integrated Risk Controls - Stock Traders Daily
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 9.6% in July - Defense World
Avalo Therapeutics (FRA:C6K0) Cash From Discontinued Investing Activities : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Oppenheimer sees upside in Avalo Therapeutics stock as phase 2 trial nears - Investing.com
Avalo Therapeutics (NASDAQ:AVTX) Releases Earnings Results - Defense World
Avalo Therapeutics sees cash runway into 2027 - TipRanks
AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024 - InvestorPlace
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates - citybiz
Avalo Therapeutics Inc expected to post a loss of $6.70 a shareEarnings Preview - XM
Natixis Lowers Stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
(AVTX) Long Term Investment Analysis - Stock Traders Daily
The 3 Best Personalized Nutrition Stocks to Buy Now - InvestorPlace
Avalo Therapeutics (NASDAQ:AVTX) Shares Down 2.1% - Defense World
Avalo Therapeutics welcomes new Chief Medical Officer - Investing.com
Avalo Therapeutics Welcomes Chief Medical Officer - Contract Pharma
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer - GlobeNewswire Inc.
Avalo Therapeutics begins Phase 2 trial for HS treatment By Investing.com - Investing.com South Africa
Avalo Therapeutics begins Phase 2 trial for HS treatment - Investing.com
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa - GlobeNewswire
(AVTX) Technical Data - Stock Traders Daily
Avalo Therapeutics Names Seasoned Pharma Atty As CLO - Law360
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Significant Decrease in Short Interest - Defense World
Form DEFA14A Avalo Therapeutics, Inc. - StreetInsider.com
Avalo Therapeutics appoints new Chief Legal Officer By Investing.com - Investing.com Australia
Avalo Therapeutics Appoints Paul Varki as Chief Legal Officer - citybiz
Avalo Therapeutics appoints new Chief Legal Officer - Investing.com India
Matson CEO Cox sells over $1m in company stock By Investing.com - Investing.com
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):